Recognitions, Agreements, Study Results, Data Presentations, and Financial Results - Analyst Notes on Baxter, Incyte, Isis, Celldex Therapeutics, Inc. and Agilent

NEW YORK, May 19, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), Incyte Corporation (NASDAQ: INCY), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), Celldex Therapeutics, Inc. (NASDAQ: CLDX) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2608-100free.

Baxter International Inc. Analyst Notes
On May 13, 2014, Baxter International Inc. (Baxter) reported that Stuart H. Altman, Ph.D., has been named the winner of 2014 William B. Graham Prize for Health Services Research. Funded by The Baxter International Foundation and managed by the Association of University Programs in Health Administration (AUPHA), the prize will be awarded to Dr. Altman on June 19, 2014, during the AUPHA Annual Meeting in San Antonio, Texas. The award recipients are selected by an independent committee of past winners, distinguished academics, and internationally recognized researchers every year. The full analyst notes on Baxter are available to download free of charge at:

http://www.analystsreview.com/2608-BAX-19May2014.pdf

Incyte Corporation Analyst Notes
On May 14, 2014, Incyte Corporation (Incyte) announced that it has collaborated with MedImmune, the global biologics research and development arm of AstraZeneca, to conduct Immuno-Oncology Combination Clinical Trial. The Company informed that the Phase I/II oncology study will evaluate the efficacy and safety of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, together with Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360. As per the terms of the agreement, MedImmune and Incyte will collaborate on a non-exclusive basis on the study, to evaluate the combination in multiple solid tumors including metastatic melanoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck and pancreatic cancer. The full analyst notes on Incyte are available to download free of charge at:

http://www.analystsreview.com/2608-INCY-19May2014.pdf

Isis Pharmaceuticals, Inc. Analyst Notes
On May 14, 2014, Isis Pharmaceuticals, Inc. (Isis) reported positive results from a Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy. According to the Company, the patients treated with ISIS-GCGRRx achieved statistically significant reductions in measures of glucose control and also experienced increased plasma GLP-1 levels. The Company informed that more information from this study will be presented as a late-breaking abstract program at the American Diabetes Association 74th Scientific Sessions. Isis has also scheduled an investor event on June 15, 2014 at 7:00 a.m. PT. The full analyst notes on Isis are available to download free of charge at:

http://www.analystsreview.com/2608-ISIS-19May2014.pdf

Celldex Therapeutics, Inc. Analyst Notes
On May 14, 2014, Celldex Therapeutics, Inc. announced that data from the Company's Phase 1 study of varlilumab, a fully human monoclonal antibody targeting CD27, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 in Chicago. In a separate release that same day, the Company announced that it has entered into clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex's CD27 targeting investigational antibody in a Phase 1/2 study. Nivolumab and varlilumab are part of a new class of cancer treatments known as immunotherapies, and a preclinical data suggest the combination of these two mechanisms may enhance anti-tumor immune response compared to either agent alone. The full analyst notes on Celldex Therapeutics, Inc. are available to download free of charge at:

http://www.analystsreview.com/2608-CLDX-19May2014.pdf

Agilent Technologies Inc. Analyst Notes
On May 14, 2014, Agilent Technologies Inc. (Agilent) reported financial results for Q2 FY 2014 (period ended April 30, 2014). During the quarter, net revenues of the Company remained almost unchanged at $1.73 billion, compared with year-ago period. Agilent's revenues slightly missed the Zacks consensus estimate of $1.74 billion. While revenues from the Life Sciences and Diagnostics (LDG) and Chemical Analysis increased 1.0% YoY and 2.5% YoY, respectively, the Electronic Measurement revenues declined by 2.2% YoY during the quarter. Net income for Q2 FY 2014 came in at $150 million, or $0.45 per diluted share, as compared to $166 million, or $0.48 per diluted share, in Q2 FY 2013. Its adjusted net income of $0.72 per share was in line with the Zacks consensus estimate. For FY 2014, Agilent expects revenue to range between $6.90 billion and $7.10 billion and non-GAAP EPS to range between $2.96 and $3.16. The full analyst notes on Agilent are available to download free of charge at:

http://www.analystsreview.com/2608-A-19May2014.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

EDITOR'S NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review